Spectrum adequacy of antibiotic regimens for secondary peritonitis: A retrospective analysis in intermediate and intensive care unit patients

Annals of Clinical Microbiology and Antimicrobials

Volumn 14, Issue 1, 2015, Pages

  Steinbach, Cathérine L ^a   Töpper, Christoph ^a   Adam, Thomas ^b   Kees, Martin G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Labor Berlin GmbH   (Germany)

Author keywords

Abdominal infection; Antimicrobial management; Nosocomial infection; Secondary peritonitis; Surgery

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CIPROFLOXACIN; FLUCONAZOLE; GENTAMICIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ACTINOMYCES; ACTINOMYCES TURICENSIS; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES CACCAE; BACTEROIDES CAPILLOSUS; BACTEROIDES EGGERTHII; BACTEROIDES FRAGILIS; BACTEROIDES INTESTINALIS; BACTEROIDES OVATUS; BACTEROIDES STERCORIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CITROBACTER; CITROBACTER BRAAKII; CITROBACTER FREUNDII; CLAVISPORA LUSITANIAE; CLOSTRIDIUM; CLOSTRIDIUM FALLAX; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM SEPTICUM; CLOSTRIDIUM SORDELLII; CLOSTRIDIUM SYMBIOSUM; CLOSTRIDIUM TERTIUM; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ENTEROCOCCUS AVIUM; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS DISPAR; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; ENTEROCOCCUS HIRAE; ESCHERICHIA COLI; FEMALE; FUSOBACTERIUM NECROPHORUM; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM VARIUM; HAFNIA ALVEI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LACTOCOCCUS GARVIEAE; MAJOR CLINICAL STUDY; MALE; MORGANELLA MORGANII; NONHUMAN; PARABACTEROIDES; PARABACTEROIDES DISTASONIS; PARABACTEROIDES JOHNSONII; PEDIOCOCCUS ACIDILACTICI; PEPTOSTREPTOCOCCUS ANAEROBIUS; PERITONITIS; PICHIA KUDRIAVZEVII; PICHIA NORVEGENSIS; POSTOPERATIVE PERIOD; PREVOTELLA; PREVOTELLA DENTICOLA; PROTEUS MIRABILIS; PROTEUS PENNERI; PROTEUS VULGARIS; RETROSPECTIVE STUDY; BACTERIAL INFECTIONS; CANDIDIASIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CANDIDIASIS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONITIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84946408344     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-015-0110-4     Document Type: Article

References (18)

1. Mosdell DM, Morris DM, Voltura A, Pitcher DE, Twiest MW, Milne RL, Miscall BG, Fry DE. Antibiotic treatment for surgical peritonitis. Ann Surg. 1991;214:543-9.
2. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996;23:486-94.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections*: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-74.
4. Mayne D, Dowzicky MJ. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009). Diagn Microbiol Infect Dis. 2012;74:151-7.
5. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 2010;50:133-64.
6. Bauer AW, Perry DM, Kirby WM. Single-disk antibiotic-sensitivity testing of staphylococci; an analysis of technique and results. AMA Arch Intern Med. 1959;104:208-16.
7. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493-6.
8. Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy C-J, Steinbakk M, Winstanley TG, Kahlmeter G. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19:141-60.
9. De Waele JJ, Tellado JM, Weiss G, Alder J, Kruesmann F, Arvis P, Hussain T, Solomkin JS. Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials. Surg Infect. 2014;15:567-75.
10. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect. 2010;16:1274-81.
11. Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, Röher HD. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513-9.
12. Sotto A, Lefrant JY, Fabbro-Peray P, Muller L, Tafuri J, Navarro F, Prudhomme M, de La Coussaye JE. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother. 2002;50:569-76.
13. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother. 2009;63:785-94.
14. Blot PDS, Waele JJD, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012;72:e17-32.
15. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699-709.
16. Drug Safety and Availability-FDA Drug Safety Communication. FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning http://www.fda.gov/drugs/drugsafety/ucm369580.htm.
17. Karlowsky JA, Weaver MK, Thornsberry C, Dowzicky MJ, Jones ME, Sahm DF. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa. J Clin Microbiol. 2003;41:3339-43.
18. Ling TKW, Liu ZK, Cheng AFB. Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures. J Clin Microbiol. 2003;41:4705-7.